Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ramalingam

Showing results (171-180 of 502) with videos related to

Pageof 51
Sort By:
Health Education & Behavior : the Official Publication of the Society for Public Health Education|January 7, 2022
Intervention Characteristics Considered in Health Educators' Adoption Decision-Making ProcessThomas Strayer E, Laura E Balis, Lauren E Kennedy, et al.
Translational Oncology|March 12, 2019
The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR MutationsPuyu Shi, Shuo Zhang, Lei Zhu, et al.
American Journal of Health Promotion : AJHP|October 5, 2019
Cooperative Extension Gets Moving, but How? Exploration of Extension Health Educators' Sources and Channels for Information-Seeking PracticesThomas E Strayer, Lauren E Kennedy, Laura E Balis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2012
A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancerTaofeek K Owonikoko, Madhusmita Behera, Zhengjia Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|October 13, 2020
Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinibJiajia Gu, Luxi Qian, Guojing Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2025
Debate on first-line treatment strategies in advanced non-small cell lung cancer with EGFR mutation: An expert panel meeting by the Italian Association of Thoracic Oncology (AIOT)Cesare Gridelli, Tony Mok, Pasi Jänne, et al.
Plos One|June 23, 2011
The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivoCheng-Xiong Xu, Yikun Li, Ping Yue, et al.
Chest|May 20, 1999
Lung cancer in patients < 50 years of age: the experience of an academic multidisciplinary programS M Gadgeel, S Ramalingam, G Cummings, et al.
Iscience|September 12, 2022
Multiplexed protein profiling reveals spatial subcellular signaling networksShuangyi Cai, Thomas Hu, Mythreye Venkatesan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesotheliomaSuresh S Ramalingam, Chandra P Belani, Christopher Ruel, et al.
Pageof 51

Showing results (171-180 of 502) with videos related to

Sort By:
Pageof 51
Health Education & Behavior : the Official Publication of the Society for Public Health Education|January 7, 2022
Intervention Characteristics Considered in Health Educators' Adoption Decision-Making ProcessThomas Strayer E, Laura E Balis, Lauren E Kennedy, et al.
Translational Oncology|March 12, 2019
The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR MutationsPuyu Shi, Shuo Zhang, Lei Zhu, et al.
American Journal of Health Promotion : AJHP|October 5, 2019
Cooperative Extension Gets Moving, but How? Exploration of Extension Health Educators' Sources and Channels for Information-Seeking PracticesThomas E Strayer, Lauren E Kennedy, Laura E Balis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2012
A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancerTaofeek K Owonikoko, Madhusmita Behera, Zhengjia Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|October 13, 2020
Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinibJiajia Gu, Luxi Qian, Guojing Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2025
Debate on first-line treatment strategies in advanced non-small cell lung cancer with EGFR mutation: An expert panel meeting by the Italian Association of Thoracic Oncology (AIOT)Cesare Gridelli, Tony Mok, Pasi Jänne, et al.
Plos One|June 23, 2011
The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivoCheng-Xiong Xu, Yikun Li, Ping Yue, et al.
Chest|May 20, 1999
Lung cancer in patients < 50 years of age: the experience of an academic multidisciplinary programS M Gadgeel, S Ramalingam, G Cummings, et al.
Iscience|September 12, 2022
Multiplexed protein profiling reveals spatial subcellular signaling networksShuangyi Cai, Thomas Hu, Mythreye Venkatesan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesotheliomaSuresh S Ramalingam, Chandra P Belani, Christopher Ruel, et al.
Pageof 51